The board of directors of SSY Group Limited announced that the Group's Etomidate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Etomidate is mainly used as an anesthetic drug, and is included in the list of controlled category II psychotropic drugs of China. Currently, the Group has held the psychotropic drugs production licences in China and complied with the relevant regulations on production and management.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.